Table 1. Open in new tab Demographic and...

Characteristic^a,b	All patients on ≥1 medication and ≥18 years of age		Vedolizumab		Other IBD therapy		p-value^c
Total number of patients	3647		457	12.5%	3190	87.5%
Age
Mean [SD]	42.2	16.4	43.8	17.82	42.0	16.12	0.031
Median [IQ range]	40	29.0, 53.0	40	29.0, 55.0	40	29.0, 53.0	0.137
Female sex	1847	50.6%	239	52.3%	1608	50.4%	0.450
Race
Reported at least selected one race	3620	99.3%	454	99.3%	3166	99.2%	1.000
White	2983	81.8%	393	86.0%	2590	81.2%	0.013
Black or African American	175	4.8%	22	4.8%	153	4.8%	0.987
American Indian/Native Alaskan	8	0.2%	0	0.0%	8	0.3%	0.607
Asian	167	4.6%	8	1.8%	159	5.0%	0.002
Native Hawaiian/Pacific Islander	1	0.0%	0	0.0%	1	0.0%	1.000
Other	205	5.6%	18	3.9%	187	5.9%	0.095
Unknown	184	5.0%	20	4.4%	164	5.1%	0.485
Hispanic/Latino							<0.001
Yes	524	14.4%	50	10.9%	474	14.9%
No	2493	68.4%	349	76.4%	2144	67.2%
Unknown	403	11.1%	31	6.8%	372	11.7%
Missing	227	6.2%	27	5.9%	200	6.3%
Reporting country
USA	1319	36.2%	209	45.7%	1110	34.8%	<0.001
Spain	279	7.7%	24	5.3%	255	8.0%	0.039
Russian Federation	261	7.2%	37	8.1%	224	7.0%	0.405
UK	156	4.3%	16	3.5%	140	4.4%	0.380
France	106	2.9%	10	2.2%	96	3.0%	0.328
Italy	150	4.1%	23	5.0%	127	4.0%	0.290
Brazil	101	2.8%	9	2.0%	92	2.9%	0.265
Iran, Islamic Republic of	51	1.4%	0	0.0%	51	1.6%	0.006
Belgium	136	3.7%	22	4.8%	114	3.6%	0.191
Argentina	59	1.6%	4	0.9%	55	1.7%	0.179
Germany	99	2.7%	20	4.4%	79	2.5%	0.019
Turkey	73	2.0%	7	1.5%	66	2.1%	0.443
Netherlands	158	4.3%	13	2.8%	145	4.5%	0.095
Canada	63	1.7%	7	1.5%	56	1.8%	0.731
Other	636	17.4%	56	12.3%	580	18.2%	0.002
Disease type:							<0.001
Crohn’s disease	2049	56.2%	201	44.0%	1848	57.9%
Ulcerative colitis	1527	41.9%	246	53.8%	1281	40.2%
IBD unspecified	57	1.6%	8	1.8%	49	1.5%
IBD disease activity^d							0.149
Remission	1982	54.3%	228	49.9%	1754	55.0%
Mild	792	21.7%	104	22.8%	688	21.6%
Moderate/severe	720	19.7%	103	22.5%	617	19.3%
Smoking	145	4.0%	12	2.6%	133	4.2%	0.114
Comorbidity summary score							0.194
0	2517	69.0%	320	70.0%	2197	68.9%
1	772	21.2%	83	18.2%	689	21.6%
2	208	5.7%	33	7.2%	175	5.5%
≥3	150	4.1%	21	4.6%	129	4.0%
Cardiovascular disease	206	5.6%	25	5.5%	181	5.7%	0.860
Diabetes	178	4.9%	23	5.0%	155	4.9%	0.872
Asthma	177	4.9%	29	6.3%	148	4.6%	0.112
COPD	50	1.4%	7	1.5%	43	1.3%	0.752
Other chronic lung disease	50	1.4%	5	1.1%	45	1.4%	0.586
Hypertension	378	10.4%	41	9.0%	337	10.6%	0.296
Cancer	56	1.5%	9	2.0%	47	1.5%	0.420
History of stroke	33	0.9%	3	0.7%	30	0.9%	0.791
Chronic renal disease	71	1.9%	13	2.8%	58	1.8%	0.137
Chronic liver disease	105	2.9%	17	3.7%	88	2.8%	0.250
Other comorbidity	412	11.3%	58	12.7%	354	11.1%	0.314
BMI							0.280
BMI < 30	2440	66.9%	320	70.0%	2120	66.5%
BMI ≥ 30	609	16.7%	72	15.8%	537	16.8%
Missing	598	16.4%	65	14.2%	533	16.7%

Characteristic^a,b

All patients on ≥1 medication and ≥18 years of age

Vedolizumab

Other IBD therapy

p-value^c

Total number of patients

3647

457

12.5%

3190

87.5%

Age

Mean [SD]

42.2

16.4

43.8

17.82

42.0

16.12

0.031

Median [IQ range]

29.0, 53.0

29.0, 55.0

29.0, 53.0

0.137

Female sex

1847

50.6%

239

52.3%

1608

50.4%

0.450

Race

Reported at least selected one race

3620

99.3%

454

99.3%

3166

99.2%

1.000

White

2983

81.8%

393

86.0%

2590

81.2%

0.013

Black or African American

175

4.8%

153

4.8%

0.987

American Indian/Native Alaskan

0.2%

0.0%

0.3%

0.607

Asian

167

4.6%

1.8%

159

5.0%

0.002

Native Hawaiian/Pacific Islander

0.0%

1.000

Other

205

5.6%

3.9%

187

5.9%

0.095

Unknown

184

5.0%

4.4%

164

5.1%

0.485

Hispanic/Latino

<0.001

Yes

524

14.4%

10.9%

474

14.9%

2493

68.4%

349

76.4%

2144

67.2%

Unknown

403

11.1%

6.8%

372

11.7%

Missing

227

6.2%

5.9%

200

6.3%

Reporting country

USA

1319

36.2%

209

45.7%

1110

34.8%

<0.001

Spain

279

7.7%

5.3%

255

8.0%

0.039

Russian Federation

261

7.2%

8.1%

224

7.0%

0.405

156

4.3%

3.5%

140

4.4%

0.380

France

106

2.9%

2.2%

3.0%

0.328

Italy

150

4.1%

5.0%

127

4.0%

0.290

Brazil

101

2.8%

2.0%

2.9%

0.265

Iran, Islamic Republic of

1.4%

0.0%

1.6%

0.006

Belgium

136

3.7%

4.8%

114

3.6%

0.191

Argentina

1.6%

0.9%

1.7%

0.179

Germany

2.7%

4.4%

2.5%

0.019

Turkey

2.0%

1.5%

2.1%

0.443

Netherlands

158

4.3%

2.8%

145

4.5%

0.095

Canada

1.7%

1.5%

1.8%

0.731

Other

636

17.4%

12.3%

580

18.2%

0.002

Disease type:

<0.001

Crohn’s disease

2049

56.2%

201

44.0%

1848

57.9%

Ulcerative colitis

1527

41.9%

246

53.8%

1281

40.2%

IBD unspecified

1.6%

1.8%

1.5%

IBD disease activity^d

0.149

Remission

1982

54.3%

228

49.9%

1754

55.0%

Mild

792

21.7%

104

22.8%

688

21.6%

Moderate/severe

720

19.7%

103

22.5%

617

19.3%

Smoking

145

4.0%

2.6%

133

4.2%

0.114

Comorbidity summary score

0.194

2517

69.0%

320

70.0%

2197

68.9%

772

21.2%

18.2%

689

21.6%

208

5.7%

7.2%

175

5.5%

≥3

150

4.1%

4.6%

129

4.0%

Cardiovascular disease

206

5.6%

5.5%

181

5.7%

0.860

Diabetes

178

4.9%

5.0%

155

4.9%

0.872

Asthma

177

4.9%

6.3%

148

4.6%

0.112

COPD

1.4%

1.5%

1.3%

0.752

Other chronic lung disease

1.4%

1.1%

1.4%

0.586

Hypertension

378

10.4%

9.0%

337

10.6%

0.296

Cancer

1.5%

2.0%

1.5%

0.420

History of stroke

0.9%

0.7%

0.9%

0.791

Chronic renal disease

1.9%

2.8%

1.8%

0.137

Chronic liver disease

105

2.9%

3.7%

2.8%

0.250

Other comorbidity

412

11.3%

12.7%

354

11.1%

0.314

BMI

0.280

BMI < 30

2440

66.9%

320

70.0%

2120

66.5%

BMI ≥ 30

609

16.7%

15.8%

537

16.8%

Missing

598

16.4%

14.2%

533

16.7%

Characteristic^a,b	All patients on ≥1 medication and ≥18 years of age		Vedolizumab		Other IBD therapy		p-value^c
Total number of patients	3647		457	12.5%	3190	87.5%
Age
Mean [SD]	42.2	16.4	43.8	17.82	42.0	16.12	0.031
Median [IQ range]	40	29.0, 53.0	40	29.0, 55.0	40	29.0, 53.0	0.137
Female sex	1847	50.6%	239	52.3%	1608	50.4%	0.450
Race
Reported at least selected one race	3620	99.3%	454	99.3%	3166	99.2%	1.000
White	2983	81.8%	393	86.0%	2590	81.2%	0.013
Black or African American	175	4.8%	22	4.8%	153	4.8%	0.987
American Indian/Native Alaskan	8	0.2%	0	0.0%	8	0.3%	0.607
Asian	167	4.6%	8	1.8%	159	5.0%	0.002
Native Hawaiian/Pacific Islander	1	0.0%	0	0.0%	1	0.0%	1.000
Other	205	5.6%	18	3.9%	187	5.9%	0.095
Unknown	184	5.0%	20	4.4%	164	5.1%	0.485
Hispanic/Latino							<0.001
Yes	524	14.4%	50	10.9%	474	14.9%
No	2493	68.4%	349	76.4%	2144	67.2%
Unknown	403	11.1%	31	6.8%	372	11.7%
Missing	227	6.2%	27	5.9%	200	6.3%
Reporting country
USA	1319	36.2%	209	45.7%	1110	34.8%	<0.001
Spain	279	7.7%	24	5.3%	255	8.0%	0.039
Russian Federation	261	7.2%	37	8.1%	224	7.0%	0.405
UK	156	4.3%	16	3.5%	140	4.4%	0.380
France	106	2.9%	10	2.2%	96	3.0%	0.328
Italy	150	4.1%	23	5.0%	127	4.0%	0.290
Brazil	101	2.8%	9	2.0%	92	2.9%	0.265
Iran, Islamic Republic of	51	1.4%	0	0.0%	51	1.6%	0.006
Belgium	136	3.7%	22	4.8%	114	3.6%	0.191
Argentina	59	1.6%	4	0.9%	55	1.7%	0.179
Germany	99	2.7%	20	4.4%	79	2.5%	0.019
Turkey	73	2.0%	7	1.5%	66	2.1%	0.443
Netherlands	158	4.3%	13	2.8%	145	4.5%	0.095
Canada	63	1.7%	7	1.5%	56	1.8%	0.731
Other	636	17.4%	56	12.3%	580	18.2%	0.002
Disease type:							<0.001
Crohn’s disease	2049	56.2%	201	44.0%	1848	57.9%
Ulcerative colitis	1527	41.9%	246	53.8%	1281	40.2%
IBD unspecified	57	1.6%	8	1.8%	49	1.5%
IBD disease activity^d							0.149
Remission	1982	54.3%	228	49.9%	1754	55.0%
Mild	792	21.7%	104	22.8%	688	21.6%
Moderate/severe	720	19.7%	103	22.5%	617	19.3%
Smoking	145	4.0%	12	2.6%	133	4.2%	0.114
Comorbidity summary score							0.194
0	2517	69.0%	320	70.0%	2197	68.9%
1	772	21.2%	83	18.2%	689	21.6%
2	208	5.7%	33	7.2%	175	5.5%
≥3	150	4.1%	21	4.6%	129	4.0%
Cardiovascular disease	206	5.6%	25	5.5%	181	5.7%	0.860
Diabetes	178	4.9%	23	5.0%	155	4.9%	0.872
Asthma	177	4.9%	29	6.3%	148	4.6%	0.112
COPD	50	1.4%	7	1.5%	43	1.3%	0.752
Other chronic lung disease	50	1.4%	5	1.1%	45	1.4%	0.586
Hypertension	378	10.4%	41	9.0%	337	10.6%	0.296
Cancer	56	1.5%	9	2.0%	47	1.5%	0.420
History of stroke	33	0.9%	3	0.7%	30	0.9%	0.791
Chronic renal disease	71	1.9%	13	2.8%	58	1.8%	0.137
Chronic liver disease	105	2.9%	17	3.7%	88	2.8%	0.250
Other comorbidity	412	11.3%	58	12.7%	354	11.1%	0.314
BMI							0.280
BMI < 30	2440	66.9%	320	70.0%	2120	66.5%
BMI ≥ 30	609	16.7%	72	15.8%	537	16.8%
Missing	598	16.4%	65	14.2%	533	16.7%

Characteristic^a,b

All patients on ≥1 medication and ≥18 years of age

Vedolizumab

Other IBD therapy

p-value^c

Total number of patients

3647

457

12.5%

3190

87.5%

Age

Mean [SD]

42.2

16.4

43.8

17.82

42.0

16.12

0.031

Median [IQ range]

29.0, 53.0

29.0, 55.0

29.0, 53.0

0.137

Female sex

1847

50.6%

239

52.3%

1608

50.4%

0.450

Race

Reported at least selected one race

3620

99.3%

454

99.3%

3166

99.2%

1.000

White

2983

81.8%

393

86.0%

2590

81.2%

0.013

Black or African American

175

4.8%

153

4.8%

0.987

American Indian/Native Alaskan

0.2%

0.0%

0.3%

0.607

Asian

167

4.6%

1.8%

159

5.0%

0.002

Native Hawaiian/Pacific Islander

0.0%

1.000

Other

205

5.6%

3.9%

187

5.9%

0.095

Unknown

184

5.0%

4.4%

164

5.1%

0.485

Hispanic/Latino

<0.001

Yes

524

14.4%

10.9%

474

14.9%

2493

68.4%

349

76.4%

2144

67.2%

Unknown

403

11.1%

6.8%

372

11.7%

Missing

227

6.2%

5.9%

200

6.3%

Reporting country

USA

1319

36.2%

209

45.7%

1110

34.8%

<0.001

Spain

279

7.7%

5.3%

255

8.0%

0.039

Russian Federation

261

7.2%

8.1%

224

7.0%

0.405

156

4.3%

3.5%

140

4.4%

0.380

France

106

2.9%

2.2%

3.0%

0.328

Italy

150

4.1%

5.0%

127

4.0%

0.290

Brazil

101

2.8%

2.0%

2.9%

0.265

Iran, Islamic Republic of

1.4%

0.0%

1.6%

0.006

Belgium

136

3.7%

4.8%

114

3.6%

0.191

Argentina

1.6%

0.9%

1.7%

0.179

Germany

2.7%

4.4%

2.5%

0.019

Turkey

2.0%

1.5%

2.1%

0.443

Netherlands

158

4.3%

2.8%

145

4.5%

0.095

Canada

1.7%

1.5%

1.8%

0.731

Other

636

17.4%

12.3%

580

18.2%

0.002

Disease type:

<0.001

Crohn’s disease

2049

56.2%

201

44.0%

1848

57.9%

Ulcerative colitis

1527

41.9%

246

53.8%

1281

40.2%

IBD unspecified

1.6%

1.8%

1.5%

IBD disease activity^d

0.149

Remission

1982

54.3%

228

49.9%

1754

55.0%

Mild

792

21.7%

104

22.8%

688

21.6%

Moderate/severe

720

19.7%

103

22.5%

617

19.3%

Smoking

145

4.0%

2.6%

133

4.2%

0.114

Comorbidity summary score

0.194

2517

69.0%

320

70.0%

2197

68.9%

772

21.2%

18.2%

689

21.6%

208

5.7%

7.2%

175

5.5%

≥3

150

4.1%

4.6%

129

4.0%

Cardiovascular disease

206

5.6%

5.5%

181

5.7%

0.860

Diabetes

178

4.9%

5.0%

155

4.9%

0.872

Asthma

177

4.9%

6.3%

148

4.6%

0.112

COPD

1.4%

1.5%

1.3%

0.752

Other chronic lung disease

1.4%

1.1%

1.4%

0.586

Hypertension

378

10.4%

9.0%

337

10.6%

0.296

Cancer

1.5%

2.0%

1.5%

0.420

History of stroke

0.9%

0.7%

0.9%

0.791

Chronic renal disease

1.9%

2.8%

1.8%

0.137

Chronic liver disease

105

2.9%

3.7%

2.8%

0.250

Other comorbidity

412

11.3%

12.7%

354

11.1%

0.314

BMI

0.280

BMI < 30

2440

66.9%

320

70.0%

2120

66.5%

BMI ≥ 30

609

16.7%

15.8%

537

16.8%

Missing

598

16.4%

14.2%

533

16.7%

Table 1.

Open in new tab

Demographic and clinical characteristics of IBD patients on vedolizumab compared with other IBD therapies in the SECURE-IBD registry

Characteristic^a,b	All patients on ≥1 medication and ≥18 years of age		Vedolizumab		Other IBD therapy		p-value^c
	N	%	N	%	N	%
Total number of patients	3647		457	12.5%	3190	87.5%
Age
Mean [SD]	42.2	16.4	43.8	17.82	42.0	16.12	0.031
Median [IQ range]	40	29.0, 53.0	40	29.0, 55.0	40	29.0, 53.0	0.137
Female sex	1847	50.6%	239	52.3%	1608	50.4%	0.450
Race
Reported at least selected one race	3620	99.3%	454	99.3%	3166	99.2%	1.000
White	2983	81.8%	393	86.0%	2590	81.2%	0.013
Black or African American	175	4.8%	22	4.8%	153	4.8%	0.987
American Indian/Native Alaskan	8	0.2%	0	0.0%	8	0.3%	0.607
Asian	167	4.6%	8	1.8%	159	5.0%	0.002
Native Hawaiian/Pacific Islander	1	0.0%	0	0.0%	1	0.0%	1.000
Other	205	5.6%	18	3.9%	187	5.9%	0.095
Unknown	184	5.0%	20	4.4%	164	5.1%	0.485
Hispanic/Latino							<0.001
Yes	524	14.4%	50	10.9%	474	14.9%
No	2493	68.4%	349	76.4%	2144	67.2%
Unknown	403	11.1%	31	6.8%	372	11.7%
Missing	227	6.2%	27	5.9%	200	6.3%
Reporting country
USA	1319	36.2%	209	45.7%	1110	34.8%	<0.001
Spain	279	7.7%	24	5.3%	255	8.0%	0.039
Russian Federation	261	7.2%	37	8.1%	224	7.0%	0.405
UK	156	4.3%	16	3.5%	140	4.4%	0.380
France	106	2.9%	10	2.2%	96	3.0%	0.328
Italy	150	4.1%	23	5.0%	127	4.0%	0.290
Brazil	101	2.8%	9	2.0%	92	2.9%	0.265
Iran, Islamic Republic of	51	1.4%	0	0.0%	51	1.6%	0.006
Belgium	136	3.7%	22	4.8%	114	3.6%	0.191
Argentina	59	1.6%	4	0.9%	55	1.7%	0.179
Germany	99	2.7%	20	4.4%	79	2.5%	0.019
Turkey	73	2.0%	7	1.5%	66	2.1%	0.443
Netherlands	158	4.3%	13	2.8%	145	4.5%	0.095
Canada	63	1.7%	7	1.5%	56	1.8%	0.731
Other	636	17.4%	56	12.3%	580	18.2%	0.002
Disease type:							<0.001
Crohn’s disease	2049	56.2%	201	44.0%	1848	57.9%
Ulcerative colitis	1527	41.9%	246	53.8%	1281	40.2%
IBD unspecified	57	1.6%	8	1.8%	49	1.5%
IBD disease activity^d							0.149
Remission	1982	54.3%	228	49.9%	1754	55.0%
Mild	792	21.7%	104	22.8%	688	21.6%
Moderate/severe	720	19.7%	103	22.5%	617	19.3%
Smoking	145	4.0%	12	2.6%	133	4.2%	0.114
Comorbidity summary score							0.194
0	2517	69.0%	320	70.0%	2197	68.9%
1	772	21.2%	83	18.2%	689	21.6%
2	208	5.7%	33	7.2%	175	5.5%
≥3	150	4.1%	21	4.6%	129	4.0%
Cardiovascular disease	206	5.6%	25	5.5%	181	5.7%	0.860
Diabetes	178	4.9%	23	5.0%	155	4.9%	0.872
Asthma	177	4.9%	29	6.3%	148	4.6%	0.112
COPD	50	1.4%	7	1.5%	43	1.3%	0.752
Other chronic lung disease	50	1.4%	5	1.1%	45	1.4%	0.586
Hypertension	378	10.4%	41	9.0%	337	10.6%	0.296
Cancer	56	1.5%	9	2.0%	47	1.5%	0.420
History of stroke	33	0.9%	3	0.7%	30	0.9%	0.791
Chronic renal disease	71	1.9%	13	2.8%	58	1.8%	0.137
Chronic liver disease	105	2.9%	17	3.7%	88	2.8%	0.250
Other comorbidity	412	11.3%	58	12.7%	354	11.1%	0.314
BMI							0.280
BMI < 30	2440	66.9%	320	70.0%	2120	66.5%
BMI ≥ 30	609	16.7%	72	15.8%	537	16.8%
Missing	598	16.4%	65	14.2%	533	16.7%

Characteristic^a,b	All patients on ≥1 medication and ≥18 years of age		Vedolizumab		Other IBD therapy		p-value^c
	N	%	N	%	N	%
Total number of patients	3647		457	12.5%	3190	87.5%
Age
Mean [SD]	42.2	16.4	43.8	17.82	42.0	16.12	0.031
Median [IQ range]	40	29.0, 53.0	40	29.0, 55.0	40	29.0, 53.0	0.137
Female sex	1847	50.6%	239	52.3%	1608	50.4%	0.450
Race
Reported at least selected one race	3620	99.3%	454	99.3%	3166	99.2%	1.000
White	2983	81.8%	393	86.0%	2590	81.2%	0.013
Black or African American	175	4.8%	22	4.8%	153	4.8%	0.987
American Indian/Native Alaskan	8	0.2%	0	0.0%	8	0.3%	0.607
Asian	167	4.6%	8	1.8%	159	5.0%	0.002
Native Hawaiian/Pacific Islander	1	0.0%	0	0.0%	1	0.0%	1.000
Other	205	5.6%	18	3.9%	187	5.9%	0.095
Unknown	184	5.0%	20	4.4%	164	5.1%	0.485
Hispanic/Latino							<0.001
Yes	524	14.4%	50	10.9%	474	14.9%
No	2493	68.4%	349	76.4%	2144	67.2%
Unknown	403	11.1%	31	6.8%	372	11.7%
Missing	227	6.2%	27	5.9%	200	6.3%
Reporting country
USA	1319	36.2%	209	45.7%	1110	34.8%	<0.001
Spain	279	7.7%	24	5.3%	255	8.0%	0.039
Russian Federation	261	7.2%	37	8.1%	224	7.0%	0.405
UK	156	4.3%	16	3.5%	140	4.4%	0.380
France	106	2.9%	10	2.2%	96	3.0%	0.328
Italy	150	4.1%	23	5.0%	127	4.0%	0.290
Brazil	101	2.8%	9	2.0%	92	2.9%	0.265
Iran, Islamic Republic of	51	1.4%	0	0.0%	51	1.6%	0.006
Belgium	136	3.7%	22	4.8%	114	3.6%	0.191
Argentina	59	1.6%	4	0.9%	55	1.7%	0.179
Germany	99	2.7%	20	4.4%	79	2.5%	0.019
Turkey	73	2.0%	7	1.5%	66	2.1%	0.443
Netherlands	158	4.3%	13	2.8%	145	4.5%	0.095
Canada	63	1.7%	7	1.5%	56	1.8%	0.731
Other	636	17.4%	56	12.3%	580	18.2%	0.002
Disease type:							<0.001
Crohn’s disease	2049	56.2%	201	44.0%	1848	57.9%
Ulcerative colitis	1527	41.9%	246	53.8%	1281	40.2%
IBD unspecified	57	1.6%	8	1.8%	49	1.5%
IBD disease activity^d							0.149
Remission	1982	54.3%	228	49.9%	1754	55.0%
Mild	792	21.7%	104	22.8%	688	21.6%
Moderate/severe	720	19.7%	103	22.5%	617	19.3%
Smoking	145	4.0%	12	2.6%	133	4.2%	0.114
Comorbidity summary score							0.194
0	2517	69.0%	320	70.0%	2197	68.9%
1	772	21.2%	83	18.2%	689	21.6%
2	208	5.7%	33	7.2%	175	5.5%
≥3	150	4.1%	21	4.6%	129	4.0%
Cardiovascular disease	206	5.6%	25	5.5%	181	5.7%	0.860
Diabetes	178	4.9%	23	5.0%	155	4.9%	0.872
Asthma	177	4.9%	29	6.3%	148	4.6%	0.112
COPD	50	1.4%	7	1.5%	43	1.3%	0.752
Other chronic lung disease	50	1.4%	5	1.1%	45	1.4%	0.586
Hypertension	378	10.4%	41	9.0%	337	10.6%	0.296
Cancer	56	1.5%	9	2.0%	47	1.5%	0.420
History of stroke	33	0.9%	3	0.7%	30	0.9%	0.791
Chronic renal disease	71	1.9%	13	2.8%	58	1.8%	0.137
Chronic liver disease	105	2.9%	17	3.7%	88	2.8%	0.250
Other comorbidity	412	11.3%	58	12.7%	354	11.1%	0.314
BMI							0.280
BMI < 30	2440	66.9%	320	70.0%	2120	66.5%
BMI ≥ 30	609	16.7%	72	15.8%	537	16.8%
Missing	598	16.4%	65	14.2%	533	16.7%

Abbreviations: COVID-19 = Coronavirus Disease 2019; ICU = intensive care unit; COPD = chronic obstructive pulmonary disease; IBD = inflammatory bowel disease; PSC = primary sclerosing cholangitis; NAFLD = non-alcoholic fatty liver disease.

^aUnless otherwise specified, percentages do not include missing values or ‘unknown’. For all characteristics, unless noted above, less than 4% of data were missing and unknown, respectively, for each category.

^bPercentages and n from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variables.

^cp-values for tests comparing variables between vedolizumab and other medication groups.

^dBy physician global assessment [PGA] at the time of COVID-19 infection.

This Feature Is Available To Subscribers Only